Guardant Health entered a strategic partnership with Zephyr AI to combine Guardant’s multimodal molecular data from its genomic testing platforms with Zephyr’s AI and machine‑learning analytics to accelerate cancer biomarker discovery. The collaboration integrates Zephyr’s models with Guardant’s Infinity AI capabilities to generate predictive biomarkers for therapy response, patient selection, and drug development. Guardant said the partnership will support biopharma R&D by enhancing signal extraction from circulating tumor DNA and other molecular modalities, aiming to speed translational biomarker programs.